A cost-benefit analysis of prenatal detection of down syndrome and neural tube defects in older mothers

1981 ◽  
Vol 10 (4) ◽  
pp. 367-378 ◽  
Author(s):  
A. D. Sadovnick ◽  
P. A. Baird ◽  
John M. Opitz
Keyword(s):  
Down Syndrome ◽  
Neural Tube ◽  
Neural Tube Defects ◽  
Cost Benefit Analysis ◽  
Cost Benefit ◽  
Benefit Analysis ◽  
Older Mothers ◽  
Prenatal Detection

scholarly journals Fetal Down syndrome screening models for developing countries; Part II: Cost-benefit analysis

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Chanane Wanapirak ◽  
Piyaluk Buddhawongsa ◽  
Woraluck Himakalasa ◽  
Auttapan Sarnwong ◽  
Theera Tongsong
Keyword(s):  
Developing Countries ◽  
Down Syndrome ◽  
Maternal Age ◽  
Cost Benefit Analysis ◽  
National Policy ◽  
Cost Benefit ◽  
Second Trimester ◽  
Benefit Analysis ◽  
Low Resource ◽  
Secondary Screening

Abstract Background To identify the most cost-beneficial model as a national policy of screening and diagnosis of fetal Down syndrome (DS) in developing countries. Methods Cost-benefit analysis (CBA) was performed based on the effectiveness and probabilities derived from a large prospective study on MSS (maternal serum screening) among Thai population. Various models including maternal age alone, STS (second trimester screen), I-S (independent screen: first or second trimester screen depending on the time of first visit), C-S (contingent serum screen) plus STS, maternal age with NIPS (non-invasive prenatal test), STS alone with NIPS, I-S with NIPS, C-S plus STS with NIPS, and Universal NIPS were compared. Results I-S with NIPS as a secondary screening was most cost-beneficial (Benefit/Cost ratio 4.28). Cost-benefit is directly related to the costs of NIPS. Conclusion In addition to simplicity and feasibility, I-S with expensive NIPS as a secondary screening is the most cost-beneficial method for low resource settings and should be included in universal healthcare coverage as a national policy. This study could be a model for developing countries or a guideline for international health organizations to help low resource countries, probably leading to a paradigm shift in prenatal diagnosis of fetal DS in the developing world.

scholarly journals Cost-Benefit Analysis of Down Syndrome Screening in Iran

2021 ◽  
Vol 13 (2) ◽  
Author(s):  
Mohsen Rezaei Hemami ◽  
Marzieh Nojomi ◽  
Ali Darvishi ◽  
Narges Mohamadi Parsa
Keyword(s):  
Down Syndrome ◽  
Cost Benefit Analysis ◽  
Cost Benefit ◽  
First Trimester ◽  
First Trimester Screening ◽  
Benefit Analysis ◽  
Tree Model ◽  
Trimester Screening ◽  
The Cost ◽  
Living Cost

Background: Down syndrome (DS) screening has been integrated into prenatal care programs in Iran. Objectives: Using cost-benefit analysis (CBA) method, this study aimed to evaluate the economic aspects of combined first trimester screening in Iran. Methods: The population of this descriptive cross-sectional study included all pregnant women in Tehran, Iran. A decision tree model was used to determine the costs and benefits of diagnosing and averting a DS fetus through screening. Direct and indirect costs of diagnosis and the incremental living costs of DS children in 2019 were calculated from societal perspective and compared with each other. Results: The cost of identifying a fetus with DS in Iran is approximately equal to 611 million Tomans (about 25,000 USD), and the incremental living cost of DS children (benefits) is about 34 million Tomans (about 2,270 USD). The net monetary benefit is negative due to the lower incremental living cost of a DS child than the cost of finding the affected fetus. Conclusions: Our results showed that the cost of finding an affected fetus is more than the incremental living cost of a DS child. Also, combined first-trimester screening test for DS brought no positive net benefits in Iran.

Cost-Benefit Analysis of Prenatal Diagnosis for Down Syndrome Using the British or the American Approach

2000 ◽  
Vol 95 (4) ◽  
pp. 577-583
Author(s):  
ANTHONY M. VINTZILEOS ◽  
CANDE V. ANANTH ◽  
JOHN C. SMULIAN ◽  
DEBRA L. DAY-SALVATORE ◽  
TRYFON BEAZOGLOU ◽  
...  
Keyword(s):  
Down Syndrome ◽  
Prenatal Diagnosis ◽  
Cost Benefit Analysis ◽  
Cost Benefit ◽  
Benefit Analysis
Sign in / Sign up

Export Citation Format

Share Document